Compare Crispr Therapeutics AG (CRSP) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kimberly Clark Corp — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Kimberly Clark Corp trades at $108.46 (market cap $36.11B). The key difference: Kimberly Clark Corp is far larger — about 6.9× Crispr Therapeutics AG's market cap, and Kimberly Clark Corp pays a 4.72% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | KMB | |
|---|---|---|
Market Cap | $5.23B | $36.11B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $134.81 |
52-Week Low | $44.34 | $93.05 |
Enterprise Value | $3.65B | $41.67B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Kimberly-Clark (KMB) trades at $108.95, up 0.86% on the day, with a neutral technical signal. The stock shows strong profitability with a net income margin of 11.79% and a high ROE of 129.43%, though revenue declined to $16.45B in 2025. Recent Q2 2026 earnings missed expectations, and the company cut its 2026 outlook due to challenges in China and softer consumer demand, as reported by Reuters on August 4, 2026.
The outlook is mixed; KMB offers a solid dividend yield and trades below the consensus price target of $113.20, but near-term headwinds from China and volatile shipments pose risks. Analyst sentiment is cautious with 61.29% hold ratings, reflecting balanced optimism for long-term value against short-term operational pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
